Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel; Trastuzumab emtansine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PERNETTA

    • Most Recent Events

    • 24 Oct 2023 Results of an ancillary sub-study assessing immune biomarkers predicting for long PFS in patients with the chemo-free anti-HER2 strategy presented at the 48th European Society for Medical Oncology Congress
    • 29 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top